Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.593.962 €): Fortschrittliches nanophotonisches Point-of-Care-Analysegerät zur schnellen und frühen Diagnose von Herz-Kreislauf-Erkrankungen Hor05.05.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Fortschrittliches nanophotonisches Point-of-Care-Analysegerät zur schnellen und frühen Diagnose von Herz-Kreislauf-Erkrankungen
The PHOCNOSIS project aims at the development and the preclinical validation of a nanotechnology-based handheld point-of-care testing (POCT) analysis device for its application in the early diagnosis of cardiovascular diseases (CVD). The diagnosis will be carried out by means of the fast (<10 minutes), ultra-sensitive (<1 ng/L) and label-free detection of multiple cardiac biomarkers, using a small volume of whole blood (<100 μL). This POCT analysis device will significantly help in the implementation of mass screening programs, with the consequent impact on clinical management, reducing also costs of treatments, and increasing survival rates. The PHOCNOSIS analysis device will be based on two state-of-the-art technological elements in order to obtain a compact and highly sensitive final device. First, an integrated micro-/nanofluidic system will be used for biomarkers separation, purification and concentration, targeting an effective concentration increase by a factor greater than 1000x for the targeted biomarkers. Then, the concentrated biomarkers will be detected using a novel nanophotonic-based sensing technique, envisaging a final combined detection limit below 1 ng/L. This novel sensing technique allows us to obtain systems which are low-cost, compact and with a lower complexity, thus making them suitable for the development of portable devices for POCT. The PHOCNOSIS project will target the deployment of disposable biochips with an envisaged cost below €3 to be used in a handheld analysis device with an envisaged cost below €3000. Special attention will be paid within the PHOCNOSIS project to explore the potential deployment and commercialisation of the analysis device, by means of the involvement of relevant academic and industrial partners, as well as end users.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Aalborg Universitet | 344.915 € |
| Art OF Technology AG | 0,00 € |
| CDA GmbH | 336.538 € |
| DB Venture Builder SL | 131.516 € |
| EV Group E. Thallner GmbH | 257.650 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 409.050 € |
| Genera Biotech SL | 49.734 € |
| Lab Analysis Life Science SL | 227.000 € |
| St George's Hospital Medical School | 315.938 € |
| Universitat Politecnica de Valencia | 1.097.891 € |
| Universiteit Twente | 423.731 € |
Quelle: https://cordis.europa.eu/project/id/634013
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
